What is NCT04512345 (and what is it testing)?
NCT04512345 is a clinical trial record on ClinicalTrials.gov. The name and the intervention listed for the study is tinidazole, meaning the trial is evaluating tinidazole’s effects in its specific condition and study population as defined by the protocol.
What condition is the trial for, and who can participate?
The condition being studied (and the eligibility criteria) are specified in the NCT04512345 registry entry under the trial’s “Conditions” and “Eligibility” sections. Those details determine who can enroll and what outcome measures the study uses (such as symptom improvement, microbiologic response, or other endpoints).
What type of trial is it (phase, design, and endpoints)?
ClinicalTrials.gov entries typically include:
- Trial phase (e.g., Phase 1/2/3 or “not applicable”)
- Study design (randomized vs. non-randomized; blinded vs. open-label)
- Primary and secondary outcomes (how tinidazole effectiveness/safety is measured)
Those exact fields for NCT04512345 are contained in the trial record itself.
Is tinidazole being compared with another treatment?
Some tinidazole studies are placebo-controlled or compare tinidazole with another standard therapy. The NCT04512345 entry will state whether there is a comparator arm and how participants are assigned.
Where can you read the official protocol details?
The most reliable place to review the study’s specifics is the NCT04512345 page on ClinicalTrials.gov, which lists the current status, locations, sponsor, arms/interventions, and outcomes.
If you paste the NCT04512345 ClinicalTrials.gov link (or the “Conditions,” “Interventions,” and “Eligibility” text from the page), I can summarize the trial’s purpose, design, endpoints, and current recruitment status precisely.